Ozempic Face Sparks $2 Billion Beauty Boom
Galderma, Natura, and L'Oreal are testing treatments to address facial sagging and volume loss caused by rapid weight loss from diabetes drugs like Ozempic, as the obesity drug market is projected to reach $150 billion in annual sales by 2030
The 'Ozempic face' phenomenon, where rapid weight loss from diabetes drugs like Ozempic leads to facial sagging and volume loss, has created a growing market for beauty and skincare companies. Galderma, Natura, and L'Oreal are testing treatments to address these concerns, capitalizing on a trend that is expected to generate significant revenue.
The obesity drug market is estimated to reach $150 billion in annual sales by 2030, according to Pfizer. This growth is driven by the increasing demand for weight-loss treatments, including GLP-1 drugs like Ozempic and Zepbound. These drugs help people lose weight by mimicking a hormone that keeps the stomach feeling full, but can also lead to loose skin on the face and body.
Galderma, a Swiss skincare firm, makes Sculptra, a treatment that stimulates natural collagen, and Restylane, a dermal filler made with hyaluronic acid. The company, along with Natura and L'Oreal, is targeting concerns known as 'Ozempic face,' a term that emerged as the diabetes drug became widely associated with weight loss.
Revenue from clinical treatments for skin laxity and facial volume loss is projected to grow from $700 million to $2 billion over the next five years, according to Boston Consulting Group. This growth is driven by the increasing demand for treatments to address the side effects of rapid weight loss, including facial sagging and volume loss.
## Why it matters The 'Ozempic face' phenomenon has significant implications for the beauty and skincare industry. As more people turn to weight-loss drugs like Ozempic, the demand for treatments to address facial sagging and volume loss is expected to increase. This trend presents a lucrative opportunity for companies like Galderma, Natura, and L'Oreal, which are well-positioned to capitalize on the growing market.
The trend is not limited to the beauty industry, as U.S. consumers taking weight-loss drugs like Ozempic have also turned to cobblers and tailors to save money while shedding pounds. This shift in consumer behavior highlights the far-reaching impact of the 'Ozempic face' phenomenon, which is expected to drive growth in various industries, from healthcare to retail.
## What happens next As the obesity drug market continues to grow, companies like Galderma, Natura, and L'Oreal are expected to play a significant role in addressing the side effects of rapid weight loss. With revenue from clinical treatments for skin laxity and facial volume loss projected to reach $2 billion over the next five years, these companies are well-positioned to capitalize on the growing demand for treatments to address 'Ozempic face.'
